These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 11527250

  • 1. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma.
    Tomari S, Shimoda T, Kawano T, Mitsuta K, Obase Y, Fukushima C, Matsuse H, Kohno S.
    Ann Allergy Asthma Immunol; 2001 Aug; 87(2):156-61. PubMed ID: 11527250
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids.
    Tsuchida T, Matsuse H, Machida I, Kondo Y, Saeki S, Tomari S, Obase Y, Matsuo N, Shimoda T, Kohno S.
    Allergy Asthma Proc; 2005 Aug; 26(4):287-91. PubMed ID: 16270722
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the combined effect of pranlukast during high-dose steroid inhalation.
    Horiguchi T, Tachikawa S, Kondo R, Miyazaki J, Sasaki Y, Banno K, Handa M.
    Arzneimittelforschung; 2002 Aug; 52(11):813-6. PubMed ID: 12489251
    [Abstract] [Full Text] [Related]

  • 4. Role of regular treatment with inhaled corticosteroid or leukotriene receptor antagonist in mild intermittent asthma.
    Tamaoki J, Isono K, Taira M, Tagaya E, Nakata J, Kawatani K, Nagai A.
    Allergy Asthma Proc; 2008 Aug; 29(2):189-96. PubMed ID: 18430318
    [Abstract] [Full Text] [Related]

  • 5. Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma.
    Horiguchi T, Tachikawa S, Kondo R, Shiga M, Hirose M, Ito T.
    Arzneimittelforschung; 2003 Aug; 53(10):714-21. PubMed ID: 14650364
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up of pulmonary function in bronchial asthma patients treated with pranlukast.
    Yanagawa H, Sugita A, Azuma M, Ogawa H, Kitamuro C, Yoneda K, Shinkawa K, Tani K, Sone S.
    Lung; 2004 Aug; 182(1):51-8. PubMed ID: 14752672
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma.
    Oosaki R, Mizushima Y, Kashii T, Kawasaki A, Kobayashi M.
    Int Arch Allergy Immunol; 1997 Sep; 114(1):97-100. PubMed ID: 9303339
    [Abstract] [Full Text] [Related]

  • 8. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma.
    Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, Hakuno H, Fukunaga K, Suzuki Y, Kanazawa M, Yamaguchi K.
    Pharmacogenetics; 2002 Oct; 12(7):565-70. PubMed ID: 12360108
    [Abstract] [Full Text] [Related]

  • 9. [Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma].
    Horiguchi T, Kondo R, Miyazaki J, Shiga M, Sugiyama M, Hirose M, Tachikawa S.
    Nihon Kokyuki Gakkai Zasshi; 2003 Oct; 41(10):696-703. PubMed ID: 14584388
    [Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of the leukotriene receptor antagonist pranlukast versus the steroid inhalant fluticasone in the therapy of aged patients with mild bronchial asthma.
    Horiguchi T, Tachikawa S, Kondo R, Miyazaki J, Shiga M, Hirose M, Kobayashi K, Hayashi N, Ohira D, Nasu T, Otake Y, Hata H.
    Arzneimittelforschung; 2007 Oct; 57(2):87-91. PubMed ID: 17396618
    [Abstract] [Full Text] [Related]

  • 11. Churg-Strauss syndrome after reduction of inhaled corticosteroid in a patient treated with pranlukast for asthma.
    Hashimoto M, Fujishima T, Tanaka H, Kon H, Saikai T, Suzuki A, Nakatsugawa M, Abe S.
    Intern Med; 2001 May; 40(5):432-4. PubMed ID: 11393418
    [Abstract] [Full Text] [Related]

  • 12. Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids.
    Yokoyama A, Kohno N, Sakai K, Hirasawa Y, Kondo K, Hiwada K.
    J Asthma; 1998 May; 35(1):57-62. PubMed ID: 9513583
    [Abstract] [Full Text] [Related]

  • 13. [Pranlukast allows reduction of inhaled steroid dose without deterioration in lung function in adult asthmatics].
    Tomita K, Hashimoto K, Matsumoto S, Nakamoto N, Tokuyasu H, Yamasaki A, Yajima H, Sasaki T, Kawasaki Y, Fukutani K.
    Arerugi; 1999 Apr; 48(4):459-65. PubMed ID: 10355150
    [Abstract] [Full Text] [Related]

  • 14. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
    O'Connor BJ, Löfdahl CG, Balter M, Szczeklik A, Boulet LP, Cairns CB.
    Respir Med; 2007 Jun; 101(6):1088-96. PubMed ID: 17360171
    [Abstract] [Full Text] [Related]

  • 15. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma.
    Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ.
    Chest; 2002 Jul; 122(1):151-9. PubMed ID: 12114351
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma.
    Nathan RA, Nolop KB, Cuss FM, Lorber RR.
    Chest; 1997 Jul; 112(1):34-9. PubMed ID: 9228354
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
    Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM.
    Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.